Occipital Lobe Epilepsy (OLE) is a focal epilepsy characterized by seizures arising from an epileptic focus in the occipital lobe. The international disease classification code is G40.109.
It accounts for approximately 5–10% of all epilepsies, and population-based studies report a prevalence of about 6%. In studies of newly diagnosed epilepsy, the proportion of occipital lobe seizures is only 1.2–1.6%, suggesting possible underdiagnosis. In neurosurgical series, it accounts for about 5%.
OLE often mimics the clinical features of other epilepsy syndromes, making diagnosis challenging. In older adults, stroke accounts for 30–40% of epilepsy causes, and cases may develop after occipital lobe infarction 6). Overall, about 63.7% of patients achieve seizure control with antiseizure medications (ASMs), while the remaining 36.3% become drug-resistant 3).
The seizure symptoms of OLE are diverse and are classified as follows.
Positive visual symptoms (most typical)
Examples of actual visual hallucinations include red, blue, and yellow hallucinations that change from a kaleidoscopic mushroom shape to a petal pattern1), a multicolored spherical object moving downward from the shoulder6), and a “blooming flower” that persists even with eyes closed4).
Negative visual symptoms
Other subjective symptoms
Ocular Motor Findings (During Seizures)
Postictal findings
Visual field findings associated with occipital lobe damage
The characteristics of visual field defects due to occipital lobe lesions are as follows.
The duration of the attack is the most important distinguishing feature. Visual symptoms in OLE are short, lasting seconds to 3 minutes, whereas migraine visual aura lasts 15–30 minutes. Also, OLE hallucinations are typically multicolored circular or spherical geometric shapes, while migraine is characterized by an expanding zigzag scintillating scotoma 1).
The causes of OLE are broadly divided into idiopathic and symptomatic.
Idiopathic OLE
Gastaut type: 0.3% of nonfebrile seizures. Onset at 3–15 years (mean 8 years). Typical features include brief elementary visual hallucinations, paroxysmal blindness, and eye deviation. EEG shows fixation-off sensitivity. Two-thirds remit by age 16; good prognosis.
Idiopathic photosensitive type: 3–15 years (mean 8 years). Triggered by video games or TV screens. GRIN2A gene involvement suggested. Sodium valproate is effective.
Symptomatic OLE
Structural lesions: Focal cortical dysplasia (FCD), periventricular heterotopia (PVH), polymicrogyria, tuberous sclerosis, vascular malformations (AVM, cavernous hemangioma), tumors, post-infarction changes, etc.
Metabolic/systemic diseases: Mitochondrial and storage diseases such as MELAS, MERRF, Lafora disease; celiac disease (CEC syndrome); nonketotic hyperglycemia (NKH).
This is a benign childhood epilepsy accounting for 6% of afebrile seizures in children. Onset occurs between 1 and 14 years of age (76% between 3 and 6 years), and an association with SCN1A mutations has been reported. Half of the seizures last 30 minutes or longer, but the total number of seizures in a lifetime is often low, ranging from 1 to 5. More than half of cases resolve within 4 years.
It varies greatly depending on the cause. Gastaut-type idiopathic occipital lobe epilepsy resolves in two-thirds of cases by age 16, with a good prognosis. In Panayiotopoulos syndrome, seizures disappear in more than half of cases within 4 years. On the other hand, cases due to structural lesions (such as cortical dysplasia) or hereditary progressive diseases (such as Lafora disease) are often intractable.
The characteristics, duration, frequency, and circumstances of visual hallucinations are taken in detail. In children, the presence of vomiting, pallor, and eye deviation is checked. Seizure duration is particularly important as it directly relates to differentiation from migraine.
This is the most important test for confirming the diagnosis of OLE.
Interictal EEG
Video EEG
Simultaneous recording of ictal EEG and seizure symptoms is possible, and it is effective for definitive diagnosis of epileptic nystagmus. During seizures, alpha-theta rhythm plus epileptiform discharges are recorded in the right temporo-occipital region, with some spreading to the contralateral occipital lobe 2).
Used to identify structural lesions. Pay attention to the following characteristic findings.
Perform the following depending on the suspected cause.
The main diseases to differentiate from OLE are shown in the table below.
| Disease | Duration of visual symptoms | Characteristics of hallucinations | Response to ASM |
|---|---|---|---|
| OLE | Seconds to 3 minutes | Multicolored circles/geometric | Effective |
| Migraine (visual aura) | 15–30 minutes | Expanding zigzag scintillating scotoma | Ineffective |
| Charles Bonnet syndrome (CBS) | Minutes to hours | Complex (animals, people) | Effective only for OLE component |
In migraine, patients are aware of visual field defects, but in OLE they may not be aware of them 1). CBS is a disinhibition phenomenon (cortical hyperexcitability) associated with visual loss, where complex hallucinations persist for a long time, whereas elementary hallucinations in OLE are short-lived and ASM is effective, which is key for differentiation 2).
Other differential diagnoses include peduncular hallucinosis, narcolepsy, delirium, psychosis, drug-induced conditions, and alcohol withdrawal. In psychogenic visual disturbance, the pupillary light reflex is preserved as in cortical blindness, making differentiation difficult in some cases.
EEG is essential for a definitive diagnosis. However, occipital onset may not be captured in a single short recording, and repeated recordings or long-term video EEG may be necessary 6). A normal EEG does not rule out OLE, and if there is strong clinical suspicion, repeated testing should be performed.
Standard treatment for OLE is pharmacotherapy with ASMs. The main ASMs and their usage are shown below.
Additionally, in NKH-related OLE, the combination of levetiracetam, insulin therapy, and blood glucose control can achieve rapid seizure cessation 4). In cases with CBS, a combination of zonisamide, levetiracetam, and lacosamide has been reported to improve seizures to about once every other day 2).
In PS, seizures are infrequent and prognosis is good, so continuous ASM is often unnecessary. For acute seizures, benzodiazepines (e.g., midazolam) are recommended for abortive therapy.
For epileptic nystagmus, antiepileptic drugs such as valproate, carbamazepine, and levetiracetam are the mainstay of treatment.
Surgery is an option for drug-resistant OLE. Seizure-free rates are reported to be 46–65%, varying by etiology.
When drug-resistant, surgery becomes an option. Overall seizure-free rates are 46–65%, rising to 85% for neoplastic lesions. However, for developmental abnormalities (e.g., cortical dysplasia), the rate is only about 45%. Postoperative visual field defects may occur, so thorough preoperative risk explanation is necessary 3).
OLE seizures spread anteriorly from the occipital focus. The spread pattern varies depending on the focus location.
There is a correspondence between the content of visual hallucinations and the cortical site. Seizures in the primary visual cortex (V1) produce elementary visual hallucinations (flashes, geometric patterns), which develop into complex hallucinations of animals, faces, and people as they spread to the visual association area 2).
Relationship between visual pathway anatomy and visual field defects
The upper lip of the calcarine sulcus in the occipital lobe is responsible for the lower visual field, and the lower lip for the upper visual field. Occipital lobe lesions corresponding to the posterior cerebral artery territory cause congruous homonymous hemianopia.
Mechanism of epileptic nystagmus
Seizure discharge propagation from the parieto-occipital cortex to the frontal eye field induces pathological saccades, resulting in epileptic nystagmus toward the contralateral side of the focus.
Pathogenesis of specific etiologies
Attempts to apply cathodal stimulation to suppress cortical excitability for the treatment of refractory OLE have been reported.
Tronrud et al. (2025) administered 2 mA, 20-minute, 5-day tDCS with the cathode electrode placed at O1 (left occipital) to a 20-year-old woman with refractory left occipital OLE who had failed multiple ASMs 3). The spike rate significantly decreased from 3.06/s before treatment to 1.49/s after treatment (p<0.001, Cohen d=2.17). However, the spike rate worsened after 2 weeks, requiring additional intervention. A previous study (Ng et al., 2018) reported a case of POLG-related epilepsy achieving long-term seizure freedom after 14 days of tDCS treatment 3).
When the same patient underwent 1 Hz, 1800 pulses, 5-day rTMS after tDCS, the spike rate increased from 2.33/s before treatment to 2.83/s after treatment, and worsening of symptoms was reported 3). Non-invasive brain stimulation methods show potential for tDCS, but rTMS may increase excitability and requires careful application. Optimization of methods, parameters, and patient selection remains an unresolved issue.
Subcortical T2 hypointensity (MRI) in hyperglycemia-induced occipital lobe seizures is reversible and disappears with improvement of blood glucose. This finding has attracted attention for its potential clinical utility as a diagnostic biomarker 4).
OIRDA has traditionally been associated with generalized epilepsies such as absence epilepsy. However, case series have reported its occurrence in focal epilepsies (CECTS, PS), and lateralized OIRDA may serve as an EEG marker suggesting focal cortical hyperexcitability 5). Accumulation of evidence through future large-scale studies is needed.
